Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aeon Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AEON
American
8731
https://aeonbiopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aeon Biopharma Inc
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
- Apr 19th, 2024 1:55 pm
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
- Mar 31st, 2024 2:53 am
AEON Biopharma Announces Redemption of Public Warrants
- Mar 29th, 2024 8:15 pm
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 29th, 2024 7:45 pm
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
- Mar 19th, 2024 8:30 pm
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
- Mar 19th, 2024 8:29 pm
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
- Jan 18th, 2024 9:05 pm
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
- Dec 12th, 2023 1:00 pm
AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements
- Nov 15th, 2023 9:49 am
AEON Biopharma Reports Third Quarter 2023 Financial Results
- Nov 13th, 2023 1:15 pm
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
- Oct 19th, 2023 8:05 pm
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
- Aug 29th, 2023 12:00 pm
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
- Aug 24th, 2023 12:00 pm
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
- Aug 16th, 2023 11:00 am
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
- Jul 24th, 2023 11:00 am
Scroll